PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report

Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal disease with limited effective treatment especially after first-line chemotherapy. The human epidermal growth factor receptor 2 (HER-2) immunohistochemistry (IHC) positive is associated with more aggressive clinical behavior and shorter overa...

Full description

Saved in:

Bibliographic Details
Published in:	World journal of gastroenterology : WJG Vol. 30; no. 9; p. 1237
Main Authors:	Kong, Yue-Hong, Xu, Mei-Ling, Zhang, Jun-Jun, Chen, Guang-Qiang, Hong, Zhi-Hui, Zhang, Hong, Dai, Xiao-Xiao, Ma, Yi-Fu, Zhao, Xiang-Rong, Zhang, Chen-Yang, Chen, Rong-Zheng, Xing, Peng-Fei, Zhang, Li-Yuan
Format:	Journal Article
Language:	English
Published:	United States 07.03.2024
Subjects:	Albumins - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Pancreatic Ductal - drug therapy Deoxycytidine - therapeutic use Female Gemcitabine Humans Immune Checkpoint Inhibitors - therapeutic use Paclitaxel - therapeutic use Pancreatic Neoplasms - drug therapy Prospective Studies Receptor, ErbB-2 PRaG 3.0 therapy Case report Novel combination therapy Human epidermal growth factor receptor 2 Pancreatic ductal adenocarcinoma
ISSN:	2219-2840, 2219-2840
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!